Recent studies demonstrate that CAR-T cells armored with Superkine IL-2 and IL-33 can remodel the tumor microenvironment, enhance antitumor immunity, and suppress the growth of multiple solid tumors, with evidence suggesting that this combination may also mitigate antigen-loss–driven resistance (43, 127). This evidence concerns the gene IL2 and neoplasm.